SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records containing laboratory data generated in the course of the Program to enable it to furnish complete and accurate information to CUSTOMER regarding the Program activities and results, including but not limited to all Preliminary Compounds, Primary Active Compounds and NeoMorph Focused Libraries identified or used in the Program and all NeoGenesis Program Intellectual Property developed during the Program. All such written records of NeoGenesis shall be open to inspection by CUSTOMER during normal business hours upon reasonable prior written notice. (b) NeoGenesis shall provide CUSTOMER with reasonably-detailed written reports describing the results of the research performed pursuant to the Program including but not limited to all Preliminary Compounds, Primary Active Compounds, Selected Compounds and NeoMorph Focused Libraries identified or used in the Program. Such reports shall be delivered to CUSTOMER at least monthly during the Program. NeoGenesis will deliver a Primary Active Compounds Report with respect to the Program work performed on each Target. NeoGenesis will also deliver a Final Target Report on each Selected Compound after optimization and screening of the NeoMorph Focused Libraries.
Appears in 2 contracts
Sources: Confidentiality Agreement (Neogenesis Pharmaceuticals Inc), Screening and Analysis Services Agreement (Neogenesis Pharmaceuticals Inc)